|
| | HR0588 | | LRB103 35954 MST 66041 r |
|
|
| 1 | | HOUSE RESOLUTION
|
| 2 | | WHEREAS, Many people living with serious mental illnesses, |
| 3 | | including bipolar disorder, major depressive disorder, |
| 4 | | schizophrenia, and schizoaffective disorder or |
| 5 | | gastrointestinal disorders such as gastroparesis, upset |
| 6 | | stomach, nausea, and vomiting, may be treated with medications |
| 7 | | that work as dopamine receptor blocking agents, including |
| 8 | | antipsychotics and antiemetics; and
|
| 9 | | WHEREAS, While ongoing treatment with these medications |
| 10 | | can be necessary, prolonged use is associated with tardive |
| 11 | | dyskinesia (TD), an involuntary movement disorder that is |
| 12 | | characterized by uncontrollable, abnormal, and repetitive |
| 13 | | movements of the face, torso, limbs, and fingers or toes; and
|
| 14 | | WHEREAS, Even mild symptoms of TD can impact people |
| 15 | | physically, socially, and emotionally; and
|
| 16 | | WHEREAS, It is estimated that TD affects approximately |
| 17 | | 600,000 people in the United States, and approximately 65 |
| 18 | | percent of people with TD have not been diagnosed, making it |
| 19 | | important to raise awareness about the symptoms; and
|
| 20 | | WHEREAS, It is important that people taking these |
| 21 | | medications be monitored for TD by a healthcare provider; |